Presbyopia is the gradual loss of near focusing ability due to aging, which typically becomes noticeable in the early to mid-40s. This condition is treated by corrective eyeglasses, refractive surgery, lens implants, and FDA-approved eye drops like Vuity, Qlosi, and Vizz. The global presbyopia market is expected to grow to $13.30 billion in 2029 from the estimated $10.70 billion in 2025, according to a report by Business Research Co., a market intelligence firm.
The stock we are bringing to your attention today is Viatris Inc. (VTRS), which is developing a product for treating presbyopia.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.